Changes in Ovarian Cancer Prognosis, Ten Years Single Center Experience

INTRODUCTION: Ovarian cancer is the fifth most common cancer in women and ranks first among the causes of death due to gynecological cancers. In our study, we aimed to evaluate the recurrence status, survival outcomes and treatment-related side effects of patients treated for ovarian cancer retrospectively. METHODS: The study is performed at Dr.Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. In this study, 160 patients with ovarian cancer who were followed up for diagnosis and treatment between January 2010 and January 2020 were analyzed retrospectively. The cases were analyzed according to the average age, histopathological types of the ovarian cancer, the stage at the time of diagnosis, the side effects associated with the chemotherapy, the progression-free survival (PFS) and overall survival (OS) rates.Log-Rank test was used to determine survival times. RESULTS: The median age of patients included in the study is 61 ± 11 (50-72). Serous epithelial ovarian cancer was the most common (80.6%) according to histopathological subgroups. When the stage distribution at the time of diagnosis was examined, it was seen that the cases were mostly diagnosed in Stage III. While the most common side effect associated with chemotherapy was alopecia (100%), the incidence of side effects other than alopecia was 51.2%. Recurrence was detected in 48.8% of the cases, and median progression-free survival was 19.1 months, and overall survival was 89.9 months in the whole group.. Overall survival was significantly low in cases with dose reduction (p <0.05).